Table
2: Characterisics of patients with tumor progression following eribulin treatment.
|
Characteristic |
N |
% |
|
Total |
88 |
100% |
|
Age |
||
|
Median, (range) |
64 (42-85) |
|
|
Subtype |
||
|
ER + and/or PgR + |
53 |
60% |
|
Dominant disease site |
||
|
Non-visceral |
21 |
24% |
|
Visceral |
67 |
76% |
|
Number of prior chemotherapy for
advanced disease |
||
|
≥
2 |
70 |
79% |
|
Total dose of eribulin |
||
|
≥ 10 mg/m2 |
35 |
40% |
|
Progression event |
||
|
In size of pre-existing lesion |
57 |
65% |
|
A new lesion or metastasis |
31 |
35% |
ER: Estrogen Receptor;
PgR: Progesterone Receptor